{
    "id": 23482,
    "fullName": "TP53 exon8",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TP53 exon 8 indicates an unspecified mutation has occurred in exon 8 of the TP53 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "exon8",
    "createDate": "06/22/2016",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6999,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR-mutant non-small cell lung cancer patients with TP53 exon 8 mutations demonstrated decreased disease control rate (42%, 5/12 vs 87%, 97/111), shorter median progression-free survival (4.2 vs 12.5 mo) and median overall survival (16.2 vs 32.3 mo) with first-line EGFR tyrosine kinase inhibitor treatment (such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib)), compared to TP53 exon 8 wild-type patients (PMID: 27780855).",
            "molecularProfile": {
                "id": 24179,
                "profileName": "EGFR mut TP53 exon8"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11253,
                    "pubMedId": 27780855,
                    "title": "Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780855"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24177,
            "profileName": "TP53 exon8",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24179,
            "profileName": "EGFR mut TP53 exon8",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31731,
            "profileName": "EGFR exon 19 del TP53 exon8",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}